XOMA Royalty Corp (XOMA) - Financial and Strategic SWOT Analysis Review
Description
XOMA Royalty Corp (XOMA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
XOMA Royalty Corporation (Xoma) is a biotech royalty aggregator. The company focuses on acquiring economic rights to future milestone and royalty payments from partnered therapeutic candidates. Its main activities involve building a portfolio through the acquisition of rights to future milestones, royalties, and commercial payments. Xoma's portfolio includes early to mid-stage clinical assets, primarily in Phase 1 and 2 development, as well as late-stage and commercial assets. The company's products and services are utilized by partners with expertise in drug development and commercialization, addressing unmet markets or offering therapeutic advantages. Xoma collaborates with partners such as Gossamer Bio, Chiesi Farmaceutici, and others to enhance its distribution network. It operates through its subsidiaries in Bermuda, the UK, and the US. Xoma is headquartered in Berkeley, California, the US.
XOMA Royalty Corp Key Recent Developments
Jan 12,2026: XOMA Royalty Announces CFO Transition
Dec 30,2025: XOMA Royalty and Takeda Amend Agreement and Execute Royalty Sharing Transaction for Mezagitamab
Nov 12,2025: XOMA Royalty Reports Third Quarter and Year to Date 2025 Financial Results
Nov 12,2025: XOMA Royalty Reports Third Quarter and Year-to-Date 2025 Financial Results and Business Highlights
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note:Some sections may be missing if data is unavailable for the company
The profile contains critical company information including:
- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
XOMA Royalty Corporation (Xoma) is a biotech royalty aggregator. The company focuses on acquiring economic rights to future milestone and royalty payments from partnered therapeutic candidates. Its main activities involve building a portfolio through the acquisition of rights to future milestones, royalties, and commercial payments. Xoma's portfolio includes early to mid-stage clinical assets, primarily in Phase 1 and 2 development, as well as late-stage and commercial assets. The company's products and services are utilized by partners with expertise in drug development and commercialization, addressing unmet markets or offering therapeutic advantages. Xoma collaborates with partners such as Gossamer Bio, Chiesi Farmaceutici, and others to enhance its distribution network. It operates through its subsidiaries in Bermuda, the UK, and the US. Xoma is headquartered in Berkeley, California, the US.
XOMA Royalty Corp Key Recent Developments
Jan 12,2026: XOMA Royalty Announces CFO Transition
Dec 30,2025: XOMA Royalty and Takeda Amend Agreement and Execute Royalty Sharing Transaction for Mezagitamab
Nov 12,2025: XOMA Royalty Reports Third Quarter and Year to Date 2025 Financial Results
Nov 12,2025: XOMA Royalty Reports Third Quarter and Year-to-Date 2025 Financial Results and Business Highlights
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note:Some sections may be missing if data is unavailable for the company
Table of Contents
58 Pages
- Section 1 - About the Company
- XOMA Royalty Corp - Key Facts
- XOMA Royalty Corp - Key Employees
- XOMA Royalty Corp - Key Employee Biographies
- XOMA Royalty Corp - Major Products and Services
- XOMA Royalty Corp - History
- XOMA Royalty Corp - Company Statement
- XOMA Royalty Corp - Locations And Subsidiaries
- Head Office
- Other Locations & Subsidiaries
- Section 2 – Company Analysis
- Company Overview
- XOMA Royalty Corp - Business Description
- Geographical Segment: Asia Pacific
- Performance
- Geographical Segment: Europe
- Performance
- Geographical Segment: Switzerland
- Performance
- Geographical Segment: U.S.
- Performance
- R&D Overview
- XOMA Royalty Corp - Corporate Strategy
- XOMA Royalty Corp - SWOT Analysis
- SWOT Analysis - Overview
- XOMA Royalty Corp - Strengths
- XOMA Royalty Corp - Weaknesses
- XOMA Royalty Corp - Opportunities
- XOMA Royalty Corp - Threats
- XOMA Royalty Corp - Key Competitors
- Section 3 – Company Financial Ratios
- Financial Ratios - Capital Market Ratios
- Financial Ratios - Annual Ratios
- Performance Chart
- Financial Performance
- Financial Ratios - Interim Ratios
- Financial Ratios - Ratio Charts
- Section 4 – Company’s Lifesciences Financial Deals and Alliances
- XOMA Royalty Corp, Pharmaceuticals & Healthcare, Deals By Year, 2020 to YTD 2026
- XOMA Royalty Corp, Pharmaceuticals & Healthcare, Deals By Type, 2020 to YTD 2026
- XOMA Royalty Corp, Recent Deals Summary
- Section 5 – Company’s Recent Developments
- Jan 12, 2026: XOMA Royalty Announces CFO Transition
- Dec 30, 2025: XOMA Royalty and Takeda Amend Agreement and Execute Royalty Sharing Transaction for Mezagitamab
- Nov 12, 2025: XOMA Royalty Reports Third Quarter and Year to Date 2025 Financial Results
- Nov 12, 2025: XOMA Royalty Reports Third Quarter and Year-to-Date 2025 Financial Results and Business Highlights
- Sep 12, 2025: Xoma AB Commences New Flow Project With Leading Mining Player
- Aug 13, 2025: XOMA Royalty Reports Second Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements
- Mar 17, 2025: XOMA Royalty Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Business Achievements
- Section 6 – Appendix
- Methodology
- Ratio Definitions
- About GlobalData
- Contact Us
- Disclaimer
- List of Tables
- XOMA Royalty Corp, Key Facts
- XOMA Royalty Corp, Key Employees
- XOMA Royalty Corp, Key Employee Biographies
- XOMA Royalty Corp, Major Products and Services
- XOMA Royalty Corp, History
- XOMA Royalty Corp, Subsidiaries
- XOMA Royalty Corp, Key Competitors
- XOMA Royalty Corp, Ratios based on current share price
- XOMA Royalty Corp, Annual Ratios
- XOMA Royalty Corp, Annual Ratios (Cont...1)
- XOMA Royalty Corp, Annual Ratios (Cont...2)
- XOMA Royalty Corp, Interim Ratios
- XOMA Royalty Corp, Pharmaceuticals & Healthcare, Deals By Year, 2020 to YTD 2026
- XOMA Royalty Corp, Pharmaceuticals & Healthcare, Deals By Type, 2020 to YTD 2026
- XOMA Royalty Corp, Recent Deals Summary
- Currency Codes
- Capital Market Ratios
- Equity Ratios
- Profitability Ratios
- Cost Ratios
- Liquidity Ratios
- Leverage Ratios
- Efficiency Ratios
- List of Figures
- XOMA Royalty Corp, Performance Chart (2020 - 2024)
- XOMA Royalty Corp, Ratio Charts
- XOMA Royalty Corp, Pharmaceuticals & Healthcare, Deals By Year, 2020 to YTD 2026
- XOMA Royalty Corp, Pharmaceuticals & Healthcare, Deals by Type, 2020 to YTD 2026
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
